The gross imbalances of cancer research must be addressed - Global cancer-research ecosystems invest billions of dollars in the development of oncological medicines and technologies, such as robotics and radiotherapy, yet comparatively little into programmes that aim to advance affordable, equitable and high-quality care and outcomes. The extraordinary growth in public and private expenditure on cancer discovery science and technologies, fuelled by the huge profits of cancer biopharmaceutical companies, has failed to create more opportunities for research in neglected areas. #Cancer#CancerCare#CancerResearch#BigPharma#researchhttps://www.nature.com/articles/d41586-023-02609-2
#IDMastodon#cancercare Annual #covid19vaccine boosting for patients undergoing #antineoplasticcancer treatments reduced risks for targeted or hormonal treatments, immunotherapy, and chemotherapy-immunotherapy combinations similarly to the general population. Patients receiving no treatment or #chemotherapy exhibited higher risks, suggesting that accelerated vaccination schedules should be considered. Patients treated with #rituximab therapy posed the highest infection risk .